Kimberly-Clark has agreed to acquire Kenvue in a $40.6 billion deal expected to close in the second half of 2026. The news allowed activist investor D.E. Shaw to break even on their position. Analyst opinions are mixed regarding the company's current status. Firms like Jefferies and BofA point to an attractive entry point and brand value, while Citi and Evercore flag risks from Tylenol and talc lawsuits in the UK and Texas. The fair value estimate for the stock was trimmed slightly to $19.33. This adjustment reflects the ongoing legal uncertainty and slightly lower growth expectations for the personal care segment.